Equillium Expands Scientific and Clinical Advisory Team
06 mai 2019 08h30 HE
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
28 mars 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan...
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
26 févr. 2019 16h07 HE
|
Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...
L’analyse de survie à long terme de l’étude de phase III randomisée démontre un bénéfice clinique évident de l’inolimomab dans le traitement de la SR-aGvHD
23 janv. 2019 09h00 HE
|
Elsalys Biotech
L’analyse de survie à long terme de l’étude de phase III randomisée démontre un bénéfice clinique évident de l’inolimomab dans le traitement de la SR-aGvHD Le suivi des patients de l’étude de phase...
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD
23 janv. 2019 09h00 HE
|
Elsalys Biotech
Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD Follow-up of INO-107 Phase III study patients up to 8.5 years is the first...
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
19 déc. 2018 08h06 HE
|
Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease
17 déc. 2018 08h05 HE
|
ExCellThera
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced...
Incysus Therapeutics Announces Presentations at 2018 ASH and HAPLO Annual Meetings
28 nov. 2018 16h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
15 nov. 2018 16h07 HE
|
Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...
Equillium to Present at Investor Conferences in November 2018
01 nov. 2018 16h07 HE
|
Equillium, Inc.
LA JOLLA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...